Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Warning Letters Special Report: Where Investigations By Prescription Drug Product Firms Fell Short

Apr 05 2023

• By Bowman Cox

2022 Warning Letters Special Report — a closer look at what went wrong • Source: Shutterstock

Related Content

Halol Plant Approvals Still On Hold As Sun Responds To Lengthy FDA Inspection Report

Jun 03 2022

The Quality Lowdown: US FDA Warning Letters, 483 Reports Hit Poor Sterility And Lax Investigations

Nov 16 2022

The Quality Lowdown: Key Inspection Findings At Glenmark, Centrient, Lupin, Aurobindo, Mac-Chem

Dec 15 2022

FDA Warning Letter Brings Another High-Flying Emergent CDMO Plant Down To Earth

Aug 17 2022

Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others

Mar 24 2021

PET Drugs Warning Letter: Implications For Decentralized Manufacture Of Personalized Medicines?

May 12 2022

The Quality Lowdown: Rewarding Your Best Quality Critics

Apr 29 2022

Additional Topics

United States Quality Enforcement Compliance Manufacturing Pink Sheet Perspectives BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window